A first-in-human study with T cells equipped with afamitresgene autoleucel (Afami-cel), a genetically engineered autologous specific peptide enhanced affinity receptor (SPEAR) targeting MAGE-A4, reported 4 PR and 3 SD among eight assessed patients with advanced SS [120]. Here, MAGEA4 is linked to synovial sarcoma.